Clinical Characteristics and Treatment of Multiple Myeloma with Positive Expression of CD20

Objective To analyze the clinical manifestations, diagnosis, therapy and prognosis of CD20⁺ multiple myeloma.

Methods From Jan 1, 2012 to Dec 31, 2014, there were 143 patients were diagnosed with multiple myeloma altogether, among them 8.4% (12/143) patients with CD20 positive expression.

Results The median age is 55.5(40-81) years old. Among the 12 patients with CD20 positive expression, 33.3%(4/12) cases were CD20^dim only whereas 16.7%(2/12) were CD20^bright only. The other 6 cases were positive with both CD20^bright and CD20^dim, 4 cases had more percentage of CD20^dim and 2 cases had more percentage of CD20^bright. Among 12 cases, median survival time was 22(1-40) months, 3 patients achieved CR and 4 patients were dead, 1-year overall survival was 83.3%.

Conclusion The clinical course of CD20⁺ multiple myeloma was typically similar with multiple myeloma, after treatment some can acquire complete remission, but some patients got rapid progress of the disease.